Open in interactive viewer → charts, metric popovers & call review

MediWound: A $24 Million Promise Meets an Unfunded Factory

Guidance now rests on a U.S. government check management admits may never arrive — and the VALUE readout has quietly slid to mid-2027.
MDWD · Earnings Call · 2026-11-12

The guidance that quietly stopped being guidance

For two consecutive quarters, MediWound's management repeated the same reassuring sentence about its $24 million to $26 million 2026 revenue target. In August, CFO Hani Luxenburg was emphatic that the facility delay did not matter: “we do not actually expect the current facility timeline to have material impact on our 2026 revenue guidance. Importantly, a meaningful portion of the revenue we expect in the second half is associated, as you know, with government-funded development activity and product supply under existing agreements rather than being depending on commercial supply from our expanded facility.” — Hani Luxenburg, CFO · 2026-08-13 On this call, that construction collapsed. The same guidance is now explicitly contingent on money nobody has committed. “A substantial portion of our anticipated 2026 revenue is tied to development services for this project. We do not yet know when or whether funding will be secured.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 And when pressed for the split on the Q&A, CEO Ofer Gonen declined to provide it: “it's a significant part of the $24 million to $26 million guidance. We are not prepared now to say how we break out this component of the guidance only to share that the substantial portion is tied to development services for the planned U.S.-based facility.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 That is the story of this quarter. lower revenue from development services is the company's own name for the problem — it entered the keyword set at a high rank this quarter, and it describes a 9-month revenue line of $8.1 million against $15.1 million a year earlier. To hit the bottom of the range, MediWound would need roughly $16 million to $18 million in Q4 alone, against $8.1 million across the preceding nine months. The U.S. government is not a backdrop here; it is the P&L.

The key uncertainty, and we highlighted this is the U.S.-based manufacturing facility. We are still in ongoing discussions with them, all kinds of funding discussions that I cannot get into details now, and I don't know when it will be secured.

Ofer Gonen, Chief Executive Officer · 2026-11-12

A quarter that was always going to look bad — but not for the reason you'd guess

The optics are ugly: revenue of $3.6 million versus $5.4 million, an operating loss of $8.5 million versus $6.5 million, and an adjusted EBITDA loss of $7.4 million. But the gross margin actually improved sharply to 28.5% from 16.5%, because the mix tilted toward royalty revenue. R&D of $6.2 million versus $3.5 million is the VALUE trial burning cash — management was explicit that “We expect spending on that trial to decline substantially as it reaches completion.” — Hani Luxenburg, Chief Financial Officer · 2026-11-12 The paradox worth sitting with: partner Vericel reported NexoBrid's best quarter ever, and MediWound's total revenue fell 33%. Government procurement only began in Q3, so the catch-up is still ahead. Meanwhile manufacturing facility capacity remains the binding constraint on product sales — the company sells every unit it can make, which is a lovely problem to have and a terrible one to model. Cash burn of $28.3 million through nine months against a $53.6 million year-end balance left $28.4 million at quarter-end. November's $17.25 million gross offering — plus $2 million of warrant exercises and $1.1 million more after the quarter — buys runway through the readout. That is the correct read: the balance sheet was fixed before the guidance wobble became public, which is why the stock-level consequence is a slow re-rating rather than a financing panic.

The asset nobody argues with, and the clock nobody mentions

The bull case was never really about 2026 revenue. It is that EscharEx may be the only late-stage BLA candidate in enzymatic debridement, arriving just as the CMS skin-substitute reimbursement reset clears the field of cheaper alternatives. Gonen made that case with unusual crispness: “the market has shifted after the CMS cut of the skin substitute reimbursement, companies with large wound care sales force are now looking for product approved through BLA, NDA or PMA with an established reimbursement path. To our knowledge, EscharEx is the only late-stage BLA candidate of its kind.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 He cited SANTYL's $400 million-plus annual sales and roughly $1 billion in projected U.S. peak sales — and noted that eight of the nine large wound care companies are already collaborators. That larger wound care companies framing is new to the keyword set this quarter, and it is the most strategically interesting thing said on the call. But the clock has moved, and this is the second half of the story. In March, Gonen told analysts enrollment would finish by year-end 2026: “the outcome could be the study should finish the enrollment as planned, which means 216 patients, and as we guided, it would be by the end of 2026.” — Ofer Gonen, Chief Executive Officer · 2026-03-05 By August it was Q1 2027. Today it is still Q1 2027 — with a DSMB safety review in early January and the interim sample-size reassessment at the end of that quarter, leaving a top line in mid-2027. Gonen was careful: “After that, we have around 3 months of treatment another couple of weeks of aggregating the data. So I would expect the top line results in mid-2027.” — Ofer Gonen, Chief Executive Officer · 2026-11-12 The adjacent indications are drifting the same way. Pressure ulcers and Diabetic foot ulcers were "second half of 2026" in March, "Q4 2026" in August, and are now "getting ready for initiation" with news in "the next few weeks." The European Innovation Council-supported DFU study is real and funded; its start date is not.

What actually changed

Not the science. Not the manufacturing timeline — the expanded facility modifications still complete in Q4 2026, commercial supply still second half of 2027, unchanged and internally consistent with prior calls. What changed is that the company stopped pretending a government funding conversation was a disclosure item and started treating it as the load-bearing wall of the year. Management is now effectively saying: judge us on a mid-2027 VALUE readout for a product with a plausible billion-dollar peak, and treat 2026 as a rounding error that may or may not arrive. That is defensible. It is also a different company than the one that reaffirmed $24 million to $26 million three months ago on the strength of contracts no longer described as existing. The honest version of this call is that MediWound is an EscharEx option with a NexoBrid supply constraint attached, and everything else is noise — noise that management spent two quarters telling investors was predictable.